YMU1 is a cell-permeable and nontoxic inhibitor of hTMPK (thymidylate kinase) that sensitizes tumor cells to doxorubicin in vitro and in vivo.
Features and Benefits
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.